Latest Coronary stent Stories

Delayed Healing of Coronary Artery Following Implantation of Drug Eluting Stents, Increasing Risk of Thrombosis, is a Top Concern of Interventional Cardiologists, International Survey Shows

2013-05-21 04:20:47

PARIS, May 21, 2013 /PRNewswire/ -- The delayed healing of the coronary artery following physicians' use of drug eluting stents (DES), which increases patients' risks of developing thrombosis, is a top concern today of interventional cardiologists, according to the results of a survey announced at EuroPCR 2013 in Paris. In the online survey of 141 interventional cardiologists in Belgium, China, Denmark, Germany, Italy, Malaysia, The Netherlands, Singapore and the United Kingdom,...

Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device

2013-05-20 23:19:09

Allegheny General Hospital (AGH) in Pittsburgh has been selected to join the ABSORB III clinical trial, a multi-center international study exploring a unique bioresorbable vascular scaffold (BVS), a small mesh tube that is designed to open a blocked artery and then fully dissolve over time, leaving the vessel free of a permanent metallic implant. The FDA-approved study of the drug-eluting AbsorbTM BVS, made by healthcare company Abbott, is expected to enroll approximately 2,250 patients...

InspireMD to Announce Six-Month Results from the MGuard(TM) Embolic Protection Stent (EPS) MASTER Trial at EuroPCR

2013-05-16 20:22:40

BOSTON and TEL AVIV, Israel, May 16, 2013 /PRNewswire/ -- -Strong Conference Presence to Include Presentations/Educational Events Featuring the MGuard(TM) Embolic Protection Stent- - Company to Host Conference Call on Thursday, May 23rd to Review MASTER Data - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced a...

InspireMD Announces Reimbursement Coverage for MGuard(TM) Coronary Embolic Protection Stent (EPS) From Brazil's Largest Private Insurer

2013-05-16 12:30:16

- More than 18 Million Brazilians have Reimbursable Access to MGuard EPS - BOSTON and TEL AVIV, Israel, May 16, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced that it received reimbursement approval for the MGuard(TM) Coronary Embolic Protection Stent (EPS) from UNIMED, Brazil's largest private health care insurer. Alan Milinazzo, InspireMD's President and CEO said,...

Biosensors to Acquire Assets of Spectrum Dynamics

2013-05-16 08:27:27

Interventional Cardiology Pioneer Aims to Offer Improved Detection of Cardiovascular Disease SINGAPORE, May 16, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, announced on May 13, 2013 that it has entered into an agreement to acquire substantially all assets of Spectrum Dynamics, a leader in advanced functional assessment...

COMBO Dual Therapy Stent(TM) Clinical Results to Be Featured at EuroPCR 2013

2013-05-13 08:29:14

Results Will Be Presented During Symposium "Clinical Value of Anti-Restenosis and Pro-Healing COMBO Stent" and Oral Scientific Sessions HONG KONG, May 13, 2013 /PRNewswire/ -- OrbusNeich today announced that clinical results for the COMBO Dual Therapy Stent will be featured during EuroPCR 2013. Michael Haude, M.D., of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, will present results from REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered...

OrbusNeich enforces injunction against Boston Scientific in Germany

2013-05-07 12:31:03

WIESBADEN, Germany, May 7, 2013 /PRNewswire/ -- OrbusNeich Medical, Inc. and its German subsidiary, OrbusNeich Medical GmbH (collectively "OrbusNeich") announced that it has fulfilled all the requirements established by the Dusseldorf Regional Court, including posting of a performance bond and service to Counsel for the Defendants, and is today enforcing the Preliminary Injunction issued by the Court on April 30, 2013, against Boston Scientific Corporation and its German subsidiary...

Economic Growth In Latin America Fueling Strong Revenue Growth For Interventional Cardiology Devices

2013-05-02 08:37:52

Expanding Reimbursement Coverage to Drive Adoption of High-End Devices in the Long Term, According to Millennium Research Group TORONTO, May 2, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, favorable demographics and growing economies are the main factors spurring rising revenues in the Latin American interventional cardiology (IC) device market. Economic growth is contributing to increased...

Zinc: The Perfect Material For Bioabsorbable Stents?

2013-05-01 15:35:57

In 2012, more than 3 million people had stents inserted in their coronary arteries. These tiny mesh tubes prop open blood vessels healing from procedures like a balloon angioplasty, which widens arteries blocked by clots or plaque deposits. After about six months, most damaged arteries are healed and stay open on their own. The stent, however, is there for a lifetime. Most of the time, that’s not a problem, says Patrick Bowen, a doctoral student studying materials science and engineering...

OrbusNeich obtains preliminary injunction in patent infringement proceedings in Germany against Boston Scientific

2013-04-30 08:33:22

WIESBADEN, Germany, April 30, 2013 /PRNewswire/ -- Medical device manufacturer OrbusNeich Medical Inc. and its subsidiary, OrbusNeich Medical GmbH (collectively, "OrbusNeich") today announced that it has obtained a preliminary injunction from the Dusseldorf Regional Court in patent infringement proceedings against Boston Scientific Corporation (NYSE: BSX) and its German distribution subsidiary (collectively, "Boston Scientific"). In late February, OrbusNeich filed suit in the German...